Oxocrebanine inhibits the proliferation of hepatocellular carcinoma cells by promoting apoptosis and autophagy

Figure 6 Expression level of LC3 protein and phosphorylation levels of 4EBP1 and P70S6K in Hep3B2. 1-7 cells. A: Western blot analysis of LC3-I and LC3-II protein levels in Hep3B2.1-7 cells after treatment with oxocrebanine. VP16 (32.54 μmol/L) was used as a control; B: Western blot analysis data indicated that the ratio of LC3-II to LC3-I protein expression was increased with oxocrebanine treatments compared with the control group. Compared with oxocrebanine alone, the LC3-II/LC3-I ratio in the 3-MA + oxocrebanine group was significantly decreased; C: Phosphorylation level of 4EBP1 protein in Hep3B2.1-7 cells after treatment with oxocrebanine. VP16 (32.54 μmol/L) was used as a control; D: Western blot analysis data showed that the phosphorylation level of 4EBP1 was downregulated by oxocrebanine treatments compared with the control group. Compared with oxocrebanine alone, the phosphorylation level of 4EBP1 in the 3-MA + oxocrebanine group was significantly upregulated; E: Phosphorylation level of P70S6K in Hep3B2.1-7 cells after treatment with oxocrebanine. VP16 (32.54 μmol/L) was used as a control; F: Western blot analysis data showed that the phosphorylation level of P70S6K protein was downregulated by oxocrebanine treatments. Compared with oxocrebanine alone, the phosphorylation level of P70S6K protein in the 3-MA + oxocrebanine group was significantly upregulated. Data are shown as the mean ± SD. ^aP < 0.01 vs control; ^bP < 0.01 vs oxocrebanine group (n = 3).